LCAT and cardiovascular disorder: Based on the fact that recombinant human LCAT (rhLCAT) can improve lipid metabolism, rhLCAT has been developed mainly for the treatment of cardiovascular diseases, such as atherosclerosis, and has entered phase II clinical trials with promising results from earlier phase studies (60).